Insulin icodec
- Generic Name
- Insulin icodec
- Brand Names
- Awiqli
- Drug Type
- Biotech
- CAS Number
- 1188379-43-2
- Unique Ingredient Identifier
- P7YU3ED05N
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 630
- Registration Number
- NCT06807190
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- Conditions
- Diabetes, Type 2
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 404
- Registration Number
- NCT06340854
- Locations
- 🇺🇸
Advanced Investigative Medicine, Inc., Hawthorne, California, United States
🇺🇸Scripps Whittier Diabetes Inst, La Jolla, California, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States
A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT06288412
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT05823948
- Locations
- 🇺🇸
Amarillo Medical Specialists, Amarillo, Texas, United States
🇺🇸Accellacare_NC, Wilmington, North Carolina, United States
🇺🇸Desert Oasis Hlthcr Med Group, Palm Springs, California, United States
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 148
- Registration Number
- NCT05813912
- Locations
- 🇲🇾
Hospital Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia
🇲🇾Universiti Teknologi MARA, Sungai Buloh Campus, Sungai Buloh, Selangor, Malaysia
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT05790681
- Locations
- 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸Yale New Haven Hospital, Hospital Research Unit, New Haven, Connecticut, United States
🇺🇸Nemours Children's Health, Jacksonville, Florida, United States
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT05435677
- Locations
- 🇨🇳
Peking University Third Hospital, Northern branch-Phase I, Beijing, Beijing, China
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1291
- Registration Number
- NCT05352815
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇵🇹Unidade Local De Saude Da Regiao De Aveiro E.P.E., Aveiro, Portugal
🇳🇴St. Olavs Hospital HF, Trondheim, Norway
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04880850
- Locations
- 🇺🇸
UT Southwestern Med Cntr, Dallas, Texas, United States
🇯🇵Noritake Clinic, Ushiku-shi, Ibaraki, Japan
🇺🇸Amarillo Med Spec LLP, Amarillo, Texas, United States
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT04857398
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.